Advances in stem cell therapy for endometrial injury-related diseases
-
Endometrial injury-related diseases, particularly intrauterine adhesions (IUA) and injury-associated thin endometrium, are characterized by basal-layer damage, persistent inflammation, vascular insufficiency, fibrotic remodeling, impaired endogenous ...
MoreEndometrial injury-related diseases, particularly intrauterine adhesions (IUA) and injury-associated thin endometrium, are characterized by basal-layer damage, persistent inflammation, vascular insufficiency, fibrotic remodeling, impaired endogenous regeneration, and reduced endometrial receptivity. Conventional treatments, including hysteroscopic adhesiolysis, pharmacological therapy, and intrauterine barriers, can restore uterine cavity anatomy, control selected pathogenic factors, or reduce wound apposition, but they rarely reconstruct the damaged regenerative microenvironment. Stem cell-based therapies have therefore emerged as promising regenerative strategies because of their paracrine, immunomodulatory, proangiogenic, antifibrotic, and tissue-reparative effects. This review summarizes the shared pathological basis of endometrial injury-related diseases and the limitations of current treatments, then discusses direct stem cell delivery, stem cell–biomaterial combined strategies involving solid scaffolds and injectable hydrogels, and cell-free therapies based on stem cell-derived extracellular vesicles (EVs), particularly exosomes. We further highlight how biomaterials improve local retention and sustained activity while integrating anti-adhesion protection with active regeneration. Finally, we discuss key translational challenges, including model relevance, product heterogeneity, manufacturing standardization, long-term reproductive safety, and insufficient high-quality clinical evidence. This review provides a framework for advancing stem cell-based therapies toward integrated restoration of endometrial structure and fertility.
Less -
Kaiwen Yang, ... Xulin Hu
-
DOI: https://doi.org/10.70401/bmeh.2026.0041 - November 19, 2026


